These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 38411629)

  • 1. Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?
    Hashimoto K
    Eur Arch Psychiatry Clin Neurosci; 2024 Feb; ():. PubMed ID: 38411629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.
    Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD
    ACS Chem Neurosci; 2020 Mar; 11(6):864-871. PubMed ID: 32133835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
    Zhang JC; Yao W; Hashimoto K
    Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
    Wei Y; Chang L; Hashimoto K
    Mol Psychiatry; 2022 Jan; 27(1):559-573. PubMed ID: 33963284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
    Hashimoto K
    Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice.
    Qu Y; Chang L; Ma L; Wan X; Hashimoto K
    Pharmacol Biochem Behav; 2023 Jan; 222():173500. PubMed ID: 36476377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
    Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G
    Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.
    van den Berg M; Magaraggia I; Schreiber R; Hillhouse TM; Porter JH
    Psychopharmacology (Berl); 2022 Jun; 239(6):1853-1879. PubMed ID: 35348806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
    Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E
    Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT
    Sekssaoui M; Bockaert J; Marin P; Bécamel C
    Neuropsychopharmacology; 2024 Mar; 49(4):747-756. PubMed ID: 38212441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.
    Atiq MA; Baker MR; Voort JLV; Vargas MV; Choi DS
    Psychopharmacology (Berl); 2024 May; ():. PubMed ID: 38743110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New investigational agents for the treatment of major depressive disorder.
    Pochwat B; Krupa AJ; Siwek M; Szewczyk B
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1053-1066. PubMed ID: 35975761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The possible place for psychedelics in pharmacotherapy of mental disorders.
    Wojtas A
    Pharmacol Rep; 2023 Dec; 75(6):1313-1325. PubMed ID: 37934320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antidepressant actions of ketamine and its enantiomers.
    Johnston JN; Henter ID; Zarate CA
    Pharmacol Ther; 2023 Jun; 246():108431. PubMed ID: 37146727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.
    Dakwar E; Nunes EV; Hart CL; Hu MC; Foltin RW; Levin FR
    Neuropharmacology; 2018 Nov; 142():270-276. PubMed ID: 29309770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arketamine for cognitive impairment in psychiatric disorders.
    Hashimoto K
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1513-1525. PubMed ID: 36786865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.